Summary
Cel-, gen- en weefseltechnologie samenvatting
- Course
- Institution
Dit is een samenvatting te gebruiken voor het vak cel-, gen- en weefseltherapie (ATMP) binnen de master farmaceutische wetenschappen aan de VUB.
[Show more]
Seller
Follow
ayamoudallel
Content preview
Cel-gen en weefseltherapie:Inhoudstabel
A. Hoorcolleges .............................................................................................. 5
B. Inleiding .................................................................................................... 5
C. Algemeen .................................................................................................. 5
1.1. Definitie ATMP ....................................................................................... 5
1.2. Hierarchie Europese wetgeving ................................................................ 6
1.3. Classificatie van ATMP’s .......................................................................... 7
1.4. De lange weg naar de markt .................................................................... 8
1.5. Effect van ATMP vs (bio)farmaceutica ......................................................11
1.6. Link met “personalized/ precision medicine” .............................................12
1.7. Niet- klinische uitdagingen voor ATMP’s ...................................................14
1.8. Academische wereld en ATMP ontwikkeling ...............................................15
1.9. ATMP in toekomst .................................................................................17
1.10. Ethische aspecten van ATMP’s ..............................................................17
1.11. Take home messages .........................................................................18
D. Geneesmiddelen voor gentherapie: Het centrale dogma en genregulatie ..........20
1.12. Geschiedenis van de gentherapie .........................................................20
1.13. Het centrale dogma (F. Crick) ..............................................................20
1.13.1. Centrale dogma anno 1970 ...........................................................21
1.13.2. Van gen naar eiwit .......................................................................23
1.13.3. Hoe worden de genen geregeld? ....................................................25
1.13.4. Structuur van eukaryotisch mRNA ..................................................29
1.13.5. Types van mutaties ......................................................................30
1.13.6. Splice site mutaties ......................................................................33
1.14. Epigenetica .......................................................................................34
1.14.1. Aanpassingsvermogen: klassiek beeld en aangepast beeld ................34
1.14.2. De agouti muis ............................................................................35
1.14.3. Een goede opvoeding gaat generaties mee ......................................36
1.14.4. Lamarck......................................................................................38
1.14.5. Structuur van het DNA ..................................................................39
1.14.5.1. Opvouwing van DNA ..................................................................40
1.14.6. DNA en histonen vertonen modificaties ...........................................41
1.14.6.1. Epigenetische regulatie van agouti genen .....................................43
1.14.6.2. Epigenetisch effect van knuffelen.................................................44
1.14.7. Manipulatie van het epigenoom ......................................................45
1.15. Gentherapie ......................................................................................47
,1.15.1. Somatische vs kiemlijn gentherapie ................................................47
1.15.2. Principes van gentherapie .............................................................48
1.15.2.1. Gentherapie: benaderingen ........................................................52
1.15.3. Autosomaal dominante aandoeningen .............................................53
1.15.4. Autosomaal recessieve aandoeningen .............................................55
1.15.5. X-chromosoom gelinkt, recessief ....................................................56
1.15.6. X-chromosoom gelinkt, dominant ...................................................58
1.15.7. Gentherapie: vectoren ..................................................................60
1.15.7.1. Virusfamilies waarvan genvectoren zijn afgeleid ............................60
1.15.7.2. Gentherapie: virale vectoren .......................................................61
1.15.7.3. Gentherapie in de tijd ................................................................63
1.15.8. Retrovirale vectoren .....................................................................63
1.15.8.1. Retrovirussen: taxonomie ...........................................................63
1.15.8.2. Retrovirale structuur ..................................................................64
1.15.8.3. Retrovirale levenscyclus .............................................................67
1.15.8.4. Retrovirale vectoren: plasmiden en productie ................................69
1.15.8.5. Retrovirale vectoren: basisstructuur expressievector ......................72
1.15.8.6. Retrovirale vectoren: pros en cons ..............................................73
1.15.8.7. Aangeboren immuundeficiëntie ziekten ........................................74
1.15.9. Lentivirale vectoren ......................................................................80
1.15.9.1. Lentivirale structuur ...................................................................80
1.15.9.2. Lentivirale vectoren: plasmiden ...................................................81
1.15.9.3. Lentivirale vectoren: productie ....................................................84
1.15.9.4. Lentivirale vectoren: "changing coats"(= pseudotypering) ..............85
1.15.9.5. Lentivirale vectoren: promotorkeuze ............................................86
1.15.9.6. Lentivirale vs. Retrovirale vectoren ..............................................87
1.15.10. Adenovirale vectoren ....................................................................88
1.15.10.1. Adenovirus: structuur en ontwikkeling ........................................88
1.15.10.2. Targeting ................................................................................90
1.15.10.3. Adenovirale vectoren: plasmiden ...............................................90
1.15.10.4. Pros en cons ...........................................................................91
1.15.11. AAV- vectoren .............................................................................92
1.15.11.1. AAV vector: plasmide ...............................................................93
1.15.11.2. AAV- gebaseerde vectoren: serotypes ........................................94
1.15.11.3. AAV- gebaseerde vectoren: pros en cons ....................................94
1.15.11.4. De andere kant van de medaille: de eerste dode tgv gentherapie ..95
1.15.11.5. Glybera: the million dollar drug .................................................95
1.15.11.6. Gene therapy medicinal products (GTMP) ...................................98
, 1.15.11.7. Gentherapie trials en algemene informatie gentherapie ................99
E. Gene editing ........................................................................................... 102
1.16. Inleiding ......................................................................................... 102
1.17. Gene insertion vs gene editing. .......................................................... 103
1.18. Toepassingen van gene editing .......................................................... 104
1.19. Targeted DNA double strand breaks (DSBs) ......................................... 105
1.20. NHEJ vs HR ..................................................................................... 106
1.21. Hoe maken we DSB’s? ...................................................................... 108
1.22. Benaderingen voor gene editing ......................................................... 109
1.22.1. Meganuclease (20-40 bp/ enzyme) .............................................. 109
1.22.2. Zinc fingers (3 bp/finger) ............................................................ 109
1.22.3. TALEN (1 bp/ module) ................................................................ 113
1.22.4. CRISPR Cas (1 bp/base) ............................................................. 114
1.22.5. Cas9 fylogenie ........................................................................... 118
1.22.6. Toepassingen CRISPR/Cas9 ......................................................... 119
1.23. Gene editing: toepassingen in het algemeen. ....................................... 120
1.24. HIV ................................................................................................ 121
1.24.1. Structuur van het HIV virus ......................................................... 121
1.24.2. Routes van HIV transmissie ......................................................... 122
1.24.3. Mechanisme van HIV infectie ....................................................... 123
F. Inleiding immunologie .............................................................................. 127
1.25. Wat is het immuunsysteem? .............................................................. 127
1.26. Witte bloedcellen zijn de belangrijkste immuuncellen van het lichaam ..... 129
1.27. Welke cellen herkennen pathogenen? ................................................. 132
1.28. Fagocytose ...................................................................................... 133
1.29. Kenmerken van inflammatie .............................................................. 133
1.30. De inflammatoire respons ................................................................. 134
1.31. Het aangeboren immuunsysteem stuurt het adaptief immuunsysteem .... 136
1.32. Expansie van specifieke lymfocyten bij infectie .................................... 138
1.33. De B- cel ......................................................................................... 139
1.34. Antilichaam als herkenningspunt voor pathogenen ............................... 140
1.35. De T- cel ......................................................................................... 141
1.36. B-cel en T-cel receptoren .................................................................. 148
1.37. Evolutie van het immuunsysteem ....................................................... 148
1.38. Waar is het immuunsysteem? ............................................................ 149
1.39. Het mucosaal immuunsysteem .......................................................... 149
1.40. Microflora in de menselijke darm ........................................................ 150
1.41. Rol van microbiota en de Europese tegenhanger .................................. 150
, 1.42. Probiotica in het dagelijkse leven ....................................................... 151
1.43. Ilya Mechnikow, de vader van de probiotica ......................................... 151
1.44. Beschermer tegen ziekte maar ook ziekmaker ..................................... 151
1.45. Hygiëne, vaccinatie (en antibiotica) als mijlpalen in de geschiedenis van de
geneeskunde ................................................................................................ 152
1.45.1. Dodental veroorzaakt door historische pandemieën ........................ 153
1.45.2. Antisepsis ................................................................................. 153
1.45.3. Mortaliteit van kraamkoorts ......................................................... 154
1.45.4. Belangrijkste doodsoorzaken toen en nu… ..................................... 154
1.45.5. De pokken................................................................................. 154
1.45.6. Vaccinatie ................................................................................. 154
1.46. Kindvaccins ..................................................................................... 156
1.47. Impact van vaccins........................................................................... 157
1.48. Voorbeelden van vaccinatiecontroverses ............................................. 157
1.49. Polio ............................................................................................... 158
1.50. Congenitale rubella........................................................................... 158
1.51. Tetanus .......................................................................................... 158
1.52. Waarom vaccinatie een sociaal gebeuren is ......................................... 158
1.53. Huidige en toekomstige noden voor vaccinatie ..................................... 160
G. Tumor immunology and cancer immunotherapy .......................................... 161
1.54. Tumor immunology "avant la lettre" ................................................... 161
1.55. Birth of immunology ......................................................................... 161
1.56. The first case of cancer immunotherapy .............................................. 163
1.56.1. Contempory view on Coley's toxins .............................................. 170
1.57. Terug in de tijd… .............................................................................. 171
1.58. Coming from the other side: CAR T-cells ............................................. 178
H. Gastlessen .............................................................................................. 203
I. Voorbeeldvragen examen ........................................................................ 232
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller ayamoudallel. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $7.05. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
79202 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now